New advances in immonotoxin: Combination of tumor targeted therapy and immunotherapy

Xiao WEI,Fangjun CHEN,Kai XIN,Qin LIU,Lin LI,Lixia YU,Baorui. LIU
DOI: https://doi.org/10.3969/j.issn.1009-0460.2019.07.016
2019-01-01
Chinese Clinical Oncology
Abstract:Immunotoxins are chimeric proteins with a toxin moiety linked or genetically fused to a targeting moiety and can target cancer cells. The clinical applications of traditional immunotoxins are disappointing due to their high immunogenicity and poor penetrability. Nowadays genetic recombination technology has been employed to overcome the historical challenge of traditional immuno?toxins, allowing recombination immunotoxins (RITs) to be developed again and applied for various malignancies.However, the issue of immunogenicity is remaining and shows a negative correlation with clinical efficacy. Thus future researches focus on developing new strategies to modify immunotoxins that reduce immunogenicity. The review summarizes the current state and progress of immunotoxins.
What problem does this paper attempt to address?